Terrance G. Johns

Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma

Maria-del-Mar Inda, Rudy Bonavia, Akitake Mukasa et al. · Genes & Development · 2010 · 541 citations · Full text

Medicine, Cancer Biology, Oncology +17

Targeted drug delivery using genetically engineered diatom biosilica

Bahman Delalat, Vonda C. Sheppard, Soraya Rasi Ghaemi et al. · Nature Communications · 2015 · 302 citations · Full text

Pharmacy, Biotechnology, Oncology +17

A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastoma

Brett W. Stringer, Bryan W. Day, Rochelle C. J. D’Souza et al. · Scientific Reports · 2019 · 219 citations · Full text

Medicine, Cell Biology, Oncology +17

A phase I clinical trial with monoclonal antibody ch806 targeting transitional state and mutant epidermal growth factor receptors

Andrew M. Scott, Fook-Thean Lee, Niall C. Tebbutt et al. · Proceedings of the National Academy of Sciences · 2007 · 217 citations

Life Sciences, Cancer Biology, Oncology +17

Growth suppression of intracranial xenografted glioblastomas overexpressing mutant epidermal growth factor receptors by systemic administration of monoclonal antibody (mAb) 806, a novel monoclonal antibody directed to the receptor.

Kazuhiko Mishima, Terrance G. Johns, Rodney B. Luwor et al. · PubMed · 2001 · 207 citations

Medicine, Oncology, Pharmacology +17